HER-2 Gene: This Aggressive Breast Cancer Requires Targeted Treatment

Breast Cancer
Print icon

Click here for a callback from a breast health nurse navigator.

All breast cancers are not structured, and therefore not treated, the same, which is why doctors test tissue removed during biopsies to determine the type and stage of the disease.

All tissue is also tested for what is called the HER-2 gene, according to Dr. Stacy Nerenstone, a breast oncologist with the Hartford HealthCare Cancer Institute who is particularly interested in treating patients who test positive for what is a more aggressive form of breast cancer.

“HER-2 positive breast cancer affects 15 percent of patients,” she said. “Women with both early- and later-stage disease need to be treated with an agent that is directly targeted to that genetic marker.”

She added that all but the very smallest tumors need to be treated with chemotherapy as well as the HER-2 directed agents. Patients who have larger tumors (measuring more than 2 cm) or positive lymph nodes under their arm at the time of diagnosis may be offered this type of treatment before surgery.

“We treat these patients differently as HER-2 positivity is associated with much more rapidly growing cancers,” Dr. Nerenstone said. “Ironically, however, these patients also almost always respond to the chemotherapy as well as the treatment directed at the HER-2 marker.”

She noted a “very exciting” study released recently shows that when HER-2 targeted treatment is given before surgery, the patient’s response can be analyzed at the time of surgery.

“For patients who have no residual disease, Herceptin, which targets the HER-2 marker, can be given with or without the newer drug Perjeta to complete a year of treatment,” she said. “However, for patients with cancer that has persisted, we can improve the current rates by 50 percent by giving one of the newer HER-2 targeting agents such as Kadcyla to complete a year of treatment.”

The latter drug – which also has a generic form called Ado-trastuzumab emtansine, is an antibody drug combination of Trastuzumab and the cytotoxic agent Emtansine. It can be given to patients for a complete year of treatment, Dr. Nerenstone explained.

“It’s wonderful to have the option of knowing earlier if a patient is responding as we hope, or if we need to regroup with another approach. It improves a patient’s chance of ridding themselves of the disease,” she said.

Click here for a callback from a breast health nurse navigator.

For more information on breast cancer treatment at the Hartford HealthCare Cancer Institute, click here.

 

 


What's New

Pancreatic Cancer

Free Pancreatic Care Webinar June 11

The fourth leading cause of cancer death in both men and women, pancreatic cancer, is an aggressive form of the disease that often exhibits few symptoms until it is advanced. Approximately 57,000 Americans will be diagnosed with it this year, according to the American Cancer Society. About 47,000 will die...

Jeffrey A. Flaks

A Message From Hartford HealthCare CEO Jeffrey Flaks

With the concerns about coronavirus and COVID-19, I want to assure you that Hartford HealthCare is doing everything possible to protect the safety and well-being of the people and the communities we serve, and our team of healthcare providers. Our goal is to be ready and prepared for whatever is...

Quite Smoking

Trying to Quit Smoking? Here’s Some Help

Editor’s note: Initial studies have shown that if you smoke and get COVID-19, you’re 14 times more likely than nonsmokers to require intensive treatment. If you’ve considered stopping smoking, now is a good time. By Ellen Anderson Dornelas, PhD Director, Cancer Care Delivery and Disparities Research Hartford Healthcare Cancer Institute...

Pancreatic Cancer Recovery

How to Manage Pancreatic Cancer Treatment’s Side Effects

A pancreatic cancer survivor is any person who is actively facing pancreatic cancer or has faced it at some point. It could be someone who has completed treatment or a patient actively receiving chemotherapy for a limited or long-term management of their disease. Patients treated with chemotherapy experience a variety...

Breast Cancer Awareness

The New Normal for Breast Cancer Survivors

The word “patient” stems from the Latin word patiens, meaning sufferer. Until recently, a diagnosis of cancer conveyed a sense of victimhood and loss of control, hence labels such as “cancer patient” or “cancer victim.” Despite good intentions, these terms left those with a cancer diagnosis feeling isolated and somehow...